An interventional study of use of PancreasPlus app in Ductal Adenocarcinoma of Pancreas, Pancreatectomy and Caregiver, sponsored by Casa di Cura Dott. Pederzoli. Recruiting at 2 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-11.
Sponsored by Casa di Cura Dott. Pederzoli · Not applicable, Interventional, and Other
Caring for people with pancreatic cancer requires good coordination between hospital care and care at home, with different healthcare professionals working closely together. Patients are also becoming more involved in managing their own care on a daily basis. However, this active involvement can be difficult if there is poor communication with healthcare teams, differences in skills or familiarity with digital tools, or systems that do not support patient participation.
The PancreasPlus app was developed to support patients and caregivers by providing reliable information, self-monitoring tools, and a communication channel with healthcare professionals. The study aims to assess the feasibility, patient engagement, and perceived quality of routine use of the app. It is hypothesized that its use will improve engagement, perceived quality, reduce anxiety and unplanned hospital visits, without introducing technological or privacy risks. The app supports information and data collection but does not replace clinical decision-making.
Objectives
Primary objectives:
Assess feasibility and patient engagement through questionnaire completion. Evaluate perceived service quality using the Client Satisfaction Questionnaire (CSQ-8).
Secondary objectives:
Monitor unplanned hospital visits and adherence to chemotherapy. Assess anxiety (HADS-A), nutritional status, and global quality of life (PROMIS Global).
Evaluate usability and acceptability of the app (SUS, UTAUT2 short version).
Endpoints Primary endpoints include questionnaire completion rates and perceived quality (CSQ-8 score). Secondary endpoints include unplanned hospital access, chemotherapy adherence, anxiety levels, nutritional status, quality of life, and app usability/acceptability.
Methods This is a prospective, interventional, multicenter study with consecutive enrollment of eligible patients. Each participant will be followed for 3 months, with most activities conducted remotely via the app.
At baseline (T0), patients receive study information, provide consent, undergo training, register in the app, and complete initial assessments (clinical, socio-demographic, PROMIS Global, HADS-A). At 12 weeks (W12), follow-up includes all outcome questionnaires and data on unplanned hospital visits.
The app includes features such as a personal diary (symptoms, weight, BMI, appointments), interactive questionnaires with tailored feedback, and educational content on nutrition, prevention, emotional support, and patient rights.
Population Inclusion criteria: adults (≥18 years) with pancreatic cancer, access to a smartphone/tablet (or caregiver support), ability to consent, and understanding of Italian. Exclusion criteria include severe cognitive impairment, inability to use the app or complete follow-up, or withdrawal of consent.
Sample Size and Analysis A total of 185 patients will be enrolled (accounting for 10% dropout), based on an expected 70% engagement rate. Analyses will be conducted on both intention-to-observe and per-protocol populations. Engagement will be analyzed as questionnaire completion rates, while other outcomes will be analyzed using appropriate statistical models (e.g., logistic regression, ANCOVA, descriptive statistics). An interim analysis at 50% enrollment is planned to address potential low engagement.
Exclusion Criteria:
Other: use of PancreasPlus app
If the participant chooses to take part, they will be asked to use the PancreasPlus app for approximately 3 months. The app is designed to support the care pathway by helping track symptoms, weight, and other health aspects. At the beginning, the participant will receive instructions to download the app and create an account. The participant will complete short questionnaires on physical and psychological wellbeing, including anxiety levels, quality of life, and satisfaction with the app. They will also access personalized content on symptom management, diet, treatments, and emotional support. If the app detects warning signs, it will suggest contacting the healthcare team but will not make clinical decisions. All medical decisions remain the responsibility of the treating physicians. Reminder calls may be made during the study.
Feasibility and Engagement
Feasibility and engagement will be assessed as a composite indicator of operational sustainability and active participation (co-production) in routine care. This will be operationalized as the proportion of enrolled participants who complete the scheduled questionnaires at Week 12.
Time frame: 3 months
Consumer-Perceived Quality of Care (CSQ-8 Score)
Consumer-perceived quality of care will be assessed using the Client Satisfaction Questionnaire (CSQ-8; total score range: 8-32, with higher scores indicating greater satisfaction).
Time frame: 3 months
App Usability (System Usability Scale - SUS)
Usability will be assessed using the System Usability Scale (SUS). Higher scores indicate greater usability. The System Usability Scale (SUS) produces a total score ranging from a minimum of 0 to a maximum of 100. These scores represent the percentile rank of a product's perceived usability, not a percentage, with an average score typically hovering around 68. Minimum Value (0): Represents the lowest perceived usability. Maximum Value (100): Represents the highest perceived usability.
Time frame: 3 months
Global Quality of Life (PROMIS Global Health - Global Physical Health [GPH] and Global Mental Health [GMH] scores)
Change in global quality of life will be assessed using the PROMIS Global Health questionnaire (Global Physical Health \[GPH\] and Global Mental Health \[GMH\] scores). Outcome is defined as the change in scores from baseline (T0, start of app use) to Week 12. Global Physical and Global Mental Health subscales are computed separately and generally range from roughly 20 to 80 (T-score), where higher scores indicate better health.
Time frame: 3 months (Baseline (T0) to Week 12)
Anxiety (HADS-A Score)
Change in anxiety levels will be assessed using the Hospital Anxiety and Depression Scale - Anxiety subscale (HADS-A). Outcome is defined as the change in scores from baseline (T0) to Week 12. The Hospital Anxiety and Depression Scale - Anxiety subscale (HADS-A) consists of 7 items, with total scores ranging from a minimum of 0 to a maximum of 21. Higher scores indicate greater severity, generally interpreted as 0-7 (Normal), 8-10 (Mild/Borderline), 11-14 (Moderate), and 15-21 (Severe).
Time frame: 3 months (baseline (T0) to Week 12)
Unscheduled Healthcare Utilization
Number of unscheduled healthcare accesses, including emergency department visits, hospital admissions, and additional unplanned medical visits occurring during the study period.
Time frame: From baseline (T0) to 3 months (Week 12)
Chemotherapy Adherence
Adherence to chemotherapy will be assessed in adjuvant, induction, or neoadjuvant settings, including timing relative to surgery (if applicable), number of cycles completed, dose modifications, and treatment interruptions due to adverse events.
Time frame: From baseline (T0) to 3 months (Week 12)
Nutritional Status (Weight and Body Mass Index Monitoring)
Nutritional status will be assessed through patient self-monitoring of body weight and calculation of Body Mass Index (BMI). Outcome includes changes in weight and BMI over time.
Time frame: Baseline (T0) to 3 months (Week 12)
App Acceptability (Unified Theory of Acceptance and Use of Technology -UTAUT2)
Acceptability will be evaluated using the short version of the Unified Theory of Acceptance and Use of Technology (UTAUT2) questionnaire. Higher scores indicate greater acceptability.The most common approach is a 7-point scale, ranging from 1 (Strongly Disagree) to 7 (Strongly Agree)
Time frame: 3 months
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Casa di Cura Dott. Pederzoli